0001209191-23-016063.txt : 20230303 0001209191-23-016063.hdr.sgml : 20230303 20230303200946 ACCESSION NUMBER: 0001209191-23-016063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230301 FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Balthaser Kevin CENTRAL INDEX KEY: 0001957554 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 23707112 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 640 LEE ROAD, SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001957554 Balthaser Kevin C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 0 1 0 0 Chief Financial Officer Common Stock 2023-03-01 4 M 0 1475 A 2175 D Common Stock 2023-03-01 4 M 0 1100 A 3275 D Common Stock 2023-03-01 4 M 0 2375 A 5650 D Common Stock 2023-03-02 4 S 0 1000 12.289 D 4650 D Common Stock 2023-03-02 4 M 0 1500 A 6150 D Common Stock 2023-03-03 4 S 0 894 12.6281 D 5256 D Restricted Stock Units 2023-03-01 4 M 0 1475 0.00 D Common Stock 1475 0 D Restricted Stock Units 2023-03-01 4 M 0 1100 0.00 D Common Stock 1100 2200 D Restricted Stock Units 2023-03-01 4 M 0 2375 0.00 D Common Stock 2375 7125 D Restricted Stock Units 2023-03-02 4 M 0 1500 0.00 D Common Stock 1500 1500 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.96 to $12.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.47 to $12.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. /s/ Mark Ballantyne, Attorney-in-Fact 2023-03-03